Engineered exosomes, such as GEMINI-Exos armed with anti-CD3, anti-EGFR, PD-1, and OX40L, have demonstrated significant inhibition of triple-negative breast cancer in mice (41), while surface modifications like PEGylation or CD47 overexpression enhance circulation and tumour targeting (26). The gene discussed is EGFR; the disease is neoplasm.